NNIT (NNIT) Q3 2024 earnings summary

Executive summary

• Q3 2024 was more challenging than anticipated, with revenue down 1.7% year-over-year and organic growth at -1.6%, mainly due to slow recovery in data migration and a market slowdown in life sciences, especially in the US and Europe.

• Major contract wins in the US and Denmark are expected to support future growth, with one in transition and another delivered.

• Internal KPIs such as customer satisfaction and employee retention remain strong.

• Actions were taken to reduce capacity in underperforming regions, and the full-year outlook was revised downward on October 22, 2024.

• Q4 is expected to see improved growth and profitability, supported by a strong backlog and internal adjustments.

Financial highlights

• Q3 2024 revenue was DKK 444.7m, a decline of 1.7% year-over-year; organic revenue declined 1.6%.

• Group operating profit, excluding special items, fell from DKK 26.5m to DKK 17.5m; margin dropped from 5.8% to 3.9%.

• Gross margin for Q3 2024 was 25.8%, down from 27.3% in Q3 2023.

• Special items in Q3 2024 were DKK 9.4m, mainly earn-out and restructuring costs.

• Capacity reductions in the US and Europe were implemented to address overcapacity, with impact expected in Q4.

Outlook and guidance

• Full-year 2024 organic growth outlook revised down to 6%-7% from 10%; operating profit margin (excl. special items) adjusted to 6%-7% from 8%-9%.

• Q4 guidance: organic growth of 7%-11% and operating profit margin (excl. special items) of 8%-12%.

• Long-term financial aspiration of 10% annual growth remains unchanged.

• Adjustments reflect Q3 performance and ongoing market challenges.

• Key levers for Q4 include Asia turnaround, internal project completion, office relocations, restructuring data migration, and capacity adjustments.